Optimizing the time of day of influenza vaccine administratio

Not Applicable

• Conditions: Influenza vaccination; Not Applicable

• Registration Number: ISRCTN65770516
• Lead Sponsor: ational Institute for Public Health and the Environment

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-15
• Last Update Posted: 26 August 2024
• Study Completion: 2025-05-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 440

Inclusion Criteria

1. Aged 60-85 years at the time of inclusion.
2. Willing and able to come to the vaccination location at a randomly assigned timeslot.
3. Available for the follow-up period of 6 months.
4. Have provided written informed consent.

Exclusion Criteria

1. Known or suspected allergy to any of the vaccine components or having experienced a previous severe adverse reaction to any vaccine.
2. Present evidence of serious diseases demanding either regular use of oral immunosuppressive medical treatment, like corticosteroids, three months prior to study enrolment, or demanding acute use of high dose oral immunosuppressives two weeks prior study to study enrolment.
3. Receipt of an organ- or bone marrow transplant.
4. Receipt of chemotherapy in the previous year.
5. Receipt of blood products or immunoglobulins, within 3 months before study entry.
6. Known or suspected immunodeficiency, auto-immune disease, any type of cancer.
7. Known to be positive for human immunodeficiency virus, and/or hepatitis C virus and/or hepatitis B virus.
8. Receipt of any vaccine(s), including the COVID-19 vaccine, less than two weeks prior to or within one month after baseline (T0).
9. Receipt of influenza 2024/2025-season vaccine prior to or within one month after T0.

Study & Design

• Study Type: Interventional
• Study Design: Not specified